Author: Gianluigi Giuliani
Co-authors: Teresa Centoducati, Agea Luciana, Domenico Maddalena, Giuseppe Donvito, Michele Vitale, Vito Primavera
Abstract
Purpose: report the first safety outcome of brolucizumab intravitreal injection (IVT) in neovascular age-related macular degeneration (AMD) treatment in Altamura Hospital in a naïve population.This is a monocentric, retrospective, observational study in Altamura Hospital “Ospedale delle Murge – Fabio Perinei”. Clinical records from June 2021 to January 2022 of patients that received Brolucizumab IVT were reviewed. Exclusion criteria were previous intravitreal injections, an history of intraocular inflammation and less than 4 weeks follow up from the last IVT. We evaluated ocular inflammations, ocular infections, IOP rise and vascular occlusion in the follow-up examination.
24 eyes of 24 patients were included. Total number of injections performed was 72, mean number of IVT-B per patient was 3.0 (range 1–4). 1 patient received 1 injection, 3 patients 2 injections, 15 patients 3 injection and 5 patients received 4 injections. In all patients the injections were performed monthly in the loading phase (first three IVT) and after 12 weeks after the loading phase. We reported no adverse event in this cohort of patient.
Our short-term experience showed that brolucizumab have a good safety profile but a correct evaluation needs further investigation.
